New drug for brain disorders takes first safety step in healthy volunteers
NCT ID NCT06300398
First seen Feb 22, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This early-stage study tested the safety and tolerability of an experimental drug called IAMA-6 in 72 healthy adults aged 18 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects, how the drug moves through the body, and the effect of food. The goal was not to treat any disease, but to gather essential safety data for future research in neurodevelopmental disorders.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURODEVELOPMENTAL DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centro Ricerche Cliniche Di Verona S.r.l.
Verona, Italy
Conditions
Explore the condition pages connected to this study.